JP2007524105A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007524105A5 JP2007524105A5 JP2007500291A JP2007500291A JP2007524105A5 JP 2007524105 A5 JP2007524105 A5 JP 2007524105A5 JP 2007500291 A JP2007500291 A JP 2007500291A JP 2007500291 A JP2007500291 A JP 2007500291A JP 2007524105 A5 JP2007524105 A5 JP 2007524105A5
- Authority
- JP
- Japan
- Prior art keywords
- binding
- population
- partner
- agents
- bind
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000011230 binding agent Substances 0.000 claims 33
- 239000000126 substance Substances 0.000 claims 32
- 238000000034 method Methods 0.000 claims 19
- 239000012491 analyte Substances 0.000 claims 10
- 210000004027 cell Anatomy 0.000 claims 9
- 238000001514 detection method Methods 0.000 claims 9
- 239000003814 drug Substances 0.000 claims 8
- 239000012636 effector Substances 0.000 claims 7
- 229940124597 therapeutic agent Drugs 0.000 claims 7
- 102000004190 Enzymes Human genes 0.000 claims 4
- 108090000790 Enzymes Proteins 0.000 claims 4
- 206010028980 Neoplasm Diseases 0.000 claims 3
- 230000002776 aggregation Effects 0.000 claims 3
- 238000004220 aggregation Methods 0.000 claims 3
- 239000003795 chemical substances by application Substances 0.000 claims 3
- 210000000987 immune system Anatomy 0.000 claims 3
- 239000000651 prodrug Substances 0.000 claims 3
- 229940002612 prodrug Drugs 0.000 claims 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims 2
- 239000000427 antigen Substances 0.000 claims 2
- 102000036639 antigens Human genes 0.000 claims 2
- 108091007433 antigens Proteins 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 230000000873 masking effect Effects 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 108090001008 Avidin Proteins 0.000 claims 1
- 108010090804 Streptavidin Proteins 0.000 claims 1
- 230000003213 activating effect Effects 0.000 claims 1
- 229960002685 biotin Drugs 0.000 claims 1
- 235000020958 biotin Nutrition 0.000 claims 1
- 239000011616 biotin Substances 0.000 claims 1
- 238000004113 cell culture Methods 0.000 claims 1
- 238000003776 cleavage reaction Methods 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 230000002255 enzymatic effect Effects 0.000 claims 1
- 239000000463 material Substances 0.000 claims 1
- 238000013160 medical therapy Methods 0.000 claims 1
- 230000003071 parasitic effect Effects 0.000 claims 1
- 230000007017 scission Effects 0.000 claims 1
- 239000007790 solid phase Substances 0.000 claims 1
- 230000008685 targeting Effects 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0404187.7A GB0404187D0 (en) | 2004-02-25 | 2004-02-25 | Binding agents |
| PCT/GB2005/000704 WO2005083431A2 (en) | 2004-02-25 | 2005-02-25 | Binding agents |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2007524105A JP2007524105A (ja) | 2007-08-23 |
| JP2007524105A5 true JP2007524105A5 (enExample) | 2008-04-10 |
Family
ID=32050854
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007500291A Pending JP2007524105A (ja) | 2004-02-25 | 2005-02-25 | 結合物質 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20080107660A1 (enExample) |
| EP (1) | EP1723418A2 (enExample) |
| JP (1) | JP2007524105A (enExample) |
| GB (1) | GB0404187D0 (enExample) |
| WO (1) | WO2005083431A2 (enExample) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4547324B2 (ja) * | 2005-11-24 | 2010-09-22 | シャープ株式会社 | タンパク質認識構造体、タンパク質認識基板、及びこれらの製造方法 |
| GB0707870D0 (en) | 2007-04-23 | 2007-05-30 | Selected Antibodies Ltd | Assay Devices and Methods and Components for use Therein |
| GB0716160D0 (en) * | 2007-08-17 | 2007-09-26 | Biotransformations Ltd | Materials and methods for treating cancers which express folate receptors |
| JP6035009B2 (ja) | 2007-08-22 | 2016-11-30 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 活性化可能な結合ポリペプチドおよびその同定方法ならびに使用 |
| WO2010077643A1 (en) * | 2008-12-08 | 2010-07-08 | Tegopharm Corporation | Masking ligands for reversible inhibition of multivalent compounds |
| US8895702B2 (en) | 2008-12-08 | 2014-11-25 | City Of Hope | Development of masked therapeutic antibodies to limit off-target effects; application to anti-EGFR antibodies |
| EP3543256A1 (en) * | 2009-01-12 | 2019-09-25 | Cytomx Therapeutics Inc. | Modified antibody compositions, methods of making and using thereof |
| EP2398494A4 (en) | 2009-02-23 | 2015-10-28 | Cytomx Therapeutics Inc | Proproteins and their methods of use |
| US20130052192A1 (en) * | 2010-02-19 | 2013-02-28 | Novo Nordisk A/S | Activatable Constructs |
| EP2686020B1 (en) | 2011-03-17 | 2017-02-22 | The University of Birmingham | Re-directed immunotherapy |
| GB201203442D0 (en) * | 2012-02-28 | 2012-04-11 | Univ Birmingham | Immunotherapeutic molecules and uses |
| US9791436B2 (en) | 2012-09-12 | 2017-10-17 | The University Of Queensland | Protease-based biosensor |
| EA035322B1 (ru) | 2013-05-28 | 2020-05-28 | ДиЭсБи-ЮЭсЭй ЛЛК | Антитело с "запирающими" свойствами для инактивации лекарства белкового происхождения |
| WO2015035452A1 (en) | 2013-09-12 | 2015-03-19 | The University Of Queensland | Bimolecular protease-based biosensor |
| PE20210107A1 (es) | 2013-12-17 | 2021-01-19 | Genentech Inc | Anticuerpos anti-cd3 y metodos de uso |
| AU2016215604B2 (en) | 2015-02-02 | 2020-08-13 | The University Of Birmingham | Targeting moiety peptide epitope complexes having a plurality of T-cell epitopes |
| US20160362469A1 (en) * | 2015-06-12 | 2016-12-15 | Tianxin Wang | Methods for protein modification in pharmaceutical applications |
| WO2017087789A1 (en) | 2015-11-19 | 2017-05-26 | Revitope Limited | Functional antibody fragment complementation for a two-components system for redirected killing of unwanted cells |
| MX2018013341A (es) * | 2016-05-02 | 2019-09-18 | Encodia Inc | Analisis de macromoleculas que emplea la codificacion de acido nucleico. |
| CN109923128A (zh) | 2016-11-15 | 2019-06-21 | 基因泰克公司 | 用于用抗cd20/抗cd3双特异性抗体进行治疗的给药 |
| EP3551667A4 (en) | 2016-12-09 | 2020-06-17 | Seattle Genetics, Inc. | Bivalent antibodies masked by coiled coils |
| EP3585817A4 (en) * | 2017-02-22 | 2020-12-02 | Aleta Biotherapeutics Inc. | COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER |
| EP3704249B1 (en) * | 2017-10-31 | 2025-05-21 | Encodia, Inc. | Kits for analysis using nucleic acid encoding and/or label |
| CN114072499B (zh) | 2019-04-30 | 2024-08-06 | Encodia公司 | 用于制备分析物的方法和相关试剂盒 |
| IL296429A (en) * | 2020-06-19 | 2022-11-01 | Hoffmann La Roche | Protease-activated t-cell bispecific antibodies |
| WO2022098638A2 (en) | 2020-11-04 | 2022-05-12 | Genentech, Inc. | Dosing for treatment with anti-cd20/anti-cd3 bispecific antibodies |
| MX2023005130A (es) | 2020-11-04 | 2023-05-25 | Genentech Inc | Dosis subcutanea de anticuerpos biespecificos anti-cd20/anti-cd3. |
| EP4330282A1 (en) | 2021-04-30 | 2024-03-06 | F. Hoffmann-La Roche AG | Dosing for combination treatment with anti-cd20/anti-cd3 bispecific antibody and anti-cd79b antibody drug conjugate |
| KR20240007171A (ko) | 2021-05-14 | 2024-01-16 | 제넨테크, 인크. | 모수네투주맙 및 폴라투주맙 베도틴을 이용한 cd20 양성 증식성 장애의 치료 방법 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5849478A (en) * | 1986-08-14 | 1998-12-15 | Cashman; Daniel P. | Blocked-polymerase polynucleotide immunoassay method and kit |
| GB9322156D0 (en) * | 1993-10-27 | 1993-12-15 | Univ Newcastel Upon Tyne | Activation of molecules |
| US5468785A (en) * | 1994-04-15 | 1995-11-21 | University Of Akron | Cobaloxime photoinitiated free radical polymerizations |
| JP4212111B2 (ja) * | 1995-05-03 | 2009-01-21 | バイオエンハンスメンツ リミテッド | 結合能力が光開裂性分子により可逆的に阻害される二重特異性抗体 |
| AU3567099A (en) * | 1998-04-16 | 1999-11-01 | Packard Bioscience Company | Analysis of polynucleotide sequence |
| CA2335324A1 (en) * | 1998-07-17 | 2000-01-27 | Genetag Technology, Inc. | Methods for detecting and mapping genes, mutations and variant polynucleotide sequences |
| US6203989B1 (en) * | 1998-09-30 | 2001-03-20 | Affymetrix, Inc. | Methods and compositions for amplifying detectable signals in specific binding assays |
| CA2432489A1 (en) * | 2001-01-04 | 2002-08-29 | Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. | Detection of protein conformation using a split ubiquitin reporter system |
| EP1355675A1 (en) * | 2001-01-30 | 2003-10-29 | Universite Catholique De Louvain | Anti-tumor compounds |
| US20030082191A1 (en) * | 2001-08-29 | 2003-05-01 | Poduslo Joseph F. | Treatment for central nervous system disorders |
-
2004
- 2004-02-25 GB GBGB0404187.7A patent/GB0404187D0/en not_active Ceased
-
2005
- 2005-02-25 WO PCT/GB2005/000704 patent/WO2005083431A2/en not_active Ceased
- 2005-02-25 US US10/590,840 patent/US20080107660A1/en not_active Abandoned
- 2005-02-25 JP JP2007500291A patent/JP2007524105A/ja active Pending
- 2005-02-25 EP EP05717788A patent/EP1723418A2/en not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2007524105A5 (enExample) | ||
| US20080107660A1 (en) | Binding Agents | |
| Cao et al. | Bispecific antibody conjugates in therapeutics | |
| Ji et al. | Enhanced natural killer cell immunotherapy by rationally assembling Fc fragments of antibodies onto tumor membranes | |
| Fu et al. | Interactions between biomedical micro‐/nano‐motors and the immune molecules, immune cells, and the immune System: challenges and opportunities | |
| JP2002518460A5 (enExample) | ||
| Farrow et al. | A chemically synthesized capture agent enables the selective, sensitive, and robust electrochemical detection of anthrax protective antigen | |
| Yu et al. | Aptamer-based solution-gated graphene transistors for highly sensitive and real-time detection of thrombin molecules | |
| Savaliya et al. | Nanotechnology in disease diagnostic techniques | |
| JPH09506629A (ja) | ヌクレオチドに支配された生体分子および多分子薬物の集合並びに装置 | |
| JP2006523453A5 (enExample) | ||
| EE05496B1 (et) | Antikeha, mis seob osteoprotegeriini siduvat valku | |
| DE69430450D1 (de) | Zell- und serum- proteinanker und konjugate | |
| JPS6095355A (ja) | 補体経路活性化の検出方法および装置 | |
| US20190352691A1 (en) | Pathogen detection | |
| JP2005501052A5 (enExample) | ||
| EP1855719A4 (en) | NEUTRALIZING MONOCLONAL ANTIBODIES TO CORONAVIRES IN CONNECTION WITH HEAVY ACUTE RESPIRATORY SYNDROME | |
| US8118991B2 (en) | Apoenzyme reactivation electrochemical detection method and assay | |
| WO2004005531A3 (en) | Targeting and tracking of cells to specific organs and tissues in vivo | |
| WO2004102198A3 (en) | Selection of b cells with specificity of interest: method of preparation and use | |
| CN1958809A (zh) | 一种利用适配子技术检测结核分枝杆菌的方法 | |
| US10352931B2 (en) | Diagnostic device for the detection of disease related target structures | |
| DE602004015611D1 (de) | Evaluierung adjuvanshaltiger impfstoffe | |
| Dettin et al. | Chemoselective surface immobilization of proteins through a cleavable peptide | |
| Wei et al. | Flexible Site-Specific Labeling-Mediated Self-Assembly Sensor Based on Quantum Dots and LUMinescent AntiBody Sensor for Duplexed Detection of Antibodies |